Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-2 mutation (G101V) in some patients failing t...

Descripción completa

Detalles Bibliográficos
Autores principales: Birkinshaw, Richard W., Gong, Jia-nan, Luo, Cindy S., Lio, Daisy, White, Christine A., Anderson, Mary Ann, Blombery, Piers, Lessene, Guillaume, Majewski, Ian J., Thijssen, Rachel, Roberts, Andrew W., Huang, David C. S., Colman, Peter M., Czabotar, Peter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547681/
https://www.ncbi.nlm.nih.gov/pubmed/31160589
http://dx.doi.org/10.1038/s41467-019-10363-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547681/
https://www.ncbi.nlm.nih.gov/pubmed/31160589
http://dx.doi.org/10.1038/s41467-019-10363-1

Ejemplares similares